Documente Academic
Documente Profesional
Documente Cultură
Erika Maharani
Department of Cardiology and Vascular Medicine
Faculty of Medicine Universitas Gadjah Mada
Dr. Sardjito General Hospital Yogyakarta, Indonesia
Abstract
Atrial fibrillation causes the trembling of atrium and produces static of blood
that could initiate thrombus appearance, especially in left atrial appendage. Embolic
event could happen anytime if thrombus became fragile, and this condition could
initiate ischemic stroke. Atrial fibrillation confers a 5-fold higher risk of ischemic
stroke and accounts for >20% of all ischemic strokes (Saliba, 2015). AF responsible
for nearly a third of all strokes and the leading cause of embolic stroke that has worse
prognostic for patient. An integrated, structured approach to AF care, as applied
successfully to other domains of medicine will facilitate consistent, guideline-
adherent AF management for all, with the potential to improve outcomes (Kirchhof et
al., 2016).
Figure 1. Acute and chronic management of atrial fibrillation patients (Kirchoff et al.,
2016)
References
Graham, D. J., Reichman, M.E., Wernecke, M., Zhang, R., Southworth, M. R., Mott,
K., Goulding, M. R., Houston, M., MaCurdy, T.E., Worrall,, C., Kelman, J. A.
(2015). Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare
Patients Treated with Dabigatran or Warfarin for NonValvular Atrial
Fibrillation. Circulation. 131:2. 157-164
Graham, D. J., Reichman, M. E., Wernecke, M., Hsueh, Y., Izem, R., Southworth, M.
R., Kelman, J. A. (2016). Stroke, Bleeding, and Mortality Risks in Elderly
Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for
Nonvalvular Atrial Fibrillation, 176(11), 1662–1671.
https://doi.org/10.1001/jamainternmed.2016.5954
Ho, C., Ho, M., Chan, P., Hai, J., Cheung, E., Yeung, C., Leung, G. K. (2015).
Ischemic Stroke and Intracranial Hemorrhage With Aspirin , Dabigatran , and
Warfarin Impact of Quality of Anticoagulation Control, 1–8.
https://doi.org/10.1161/STROKEAHA.114.006476
Hori, M., Connolly, S. J., Zhu, J., Liu, L. S., Lau, C., Pais, P., Yusuf, S. (2013). The
online version of this article, along with updated information and services, is
located on the World Wide Web at:
https://doi.org/10.1161/STROKEAHA.113.000990
Katritsis DG, Gersh B, Camm AJ. (2015). Anticoagulation in Atrial Fibrillation-
Current Concepts. Clinical Arrhytmias and electrophysiology review.
Lim HS. Mechanism of Thrombogenesis in Atrial Fibrilation. (2011). University of
Adelaide
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino
RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. (2014). Lifetime Risk for
Development of Atrial Fibrialtion: the Framingham Heart Study;110:1042-1046
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei G, Castella M, Diener
HC, Heidibuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu
BA, Schotten U, Putte BV, Vardas P. (2016). ESC Guidelines for the
Management of Atrial Fibrillation Developed in Collaboration with EATCS.
European heart Journal.2893-2962
Nabar A, Pathan I. (2016). Pathophysiology of Atrial Fibrillation-Current Concepts.
Journal of The Association of Physician of India.
Saliba W. Non-Vitamin K Antagonist Oral Antagonist Oral Anticoagulants: New
Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs.
15:323-335
Tarokowski A, Glowniak A, Jaroszynska A, Wysokinski A. (2015). Atrial
Fibrillation-Etiology and Pathogenesis. Postepy Nauk Medycznych.